ClinicalTrials.gg
CompletedNCT04776629Updated May 11, 2026Results posted

A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors

A Phase 2 interventional study of Orticumab and Placebo in Psoriasis, Inflammation and Coronary Artery Disease, sponsored by Abcentra. Completed at 13 sites in United States. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Abcentra · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.

Enrollment
337th of 673
77 · median 77
Started
2021
with 37 others
Phase 2
200 of 764
5 open now
Registered
612th of 764
by date

Among the 764 studies in Psoriasis with a site in United States, this one is the 337th largest by enrollment of the 673 interventional ones that give a count, is one of 38 that started in 2021, is one of 200 in phase 2, and was the 612th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 764 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this proof-of-activity, phase 2 trial is to evaluate the safety and activity of orticumab in subjects with moderate to severe psoriasis and cardiometabolic risk factors.

Read the detailed description

This randomized, double-blind, study is designed to compare the effect of orticumab against placebo in subjects with moderate to severe psoriasis and cardiometabolic risk factors. A total of 75 subjects will be randomized in a double-blind fashion to receive intravenous (IV) infusions either of orticumab or placebo for up to 78 days.

Participants will be enrolled into one of the two groups: active treatment or placebo. Subjects will be randomized in a 2:1 ratio, orticumab to placebo and receive up to 11 weeks of treatment.

Planned treatments are weekly x 4 , then monthly x 2 . The Internal Safety Review Committee (ISRC) will review the blinded safety data after the first subject completes the first dose (Day 1), the first five subjects complete the first dose (Day 1), and the first ten subjects complete the first dose (Day 1). The IRSC will review all adverse reactions to all administered doses at these times.

03

Conditions studied

  • Psoriasis
  • Inflammation
  • Coronary Artery Disease
  • Cardiometabolic Syndrome
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stable/chronic plaque psoriasis with PASI score of ≥ 12 AND involving ≥ 10% of the subject's BSA.- ≥ 30 years of age at time of consent.
  • ≥ 30 kg/m2
  • LDL ≥ 100 mg/dL at Screening.
  • All females must have a negative serum pregnancy test result at Screening and a negative urine pregnancy test prior to dosing.

Exclusion criteria

Exclusion Criteria:

Subjects are excluded from the study if any of the following criteria are met:

  • Past use of orticumab.
  • Any of the nonplaque forms of psoriasis: erythrodermic, guttate, or pustular.
  • Scalp, palmar or plantar psoriasis only, at Screening or Baseline.
  • Have evidence of skin conditions (e.g., eczema) at the time of Screening or Baseline visit that would interfere with theevaluation of psoriasis.
  • Newly discovered Type 2 diabetes mellitus (T2DM)
  • Moderate or high-intensity statin use or new use of a low-intensity statin therapy.
  • No use of anti-coagulating or anti-thrombotic agents.
  • Poorly controlled hypertension
  • Use of an IL-23 blocker in the past 180 days, an IL-17 blocker in the past 16 weeks, or a TNF blocker in the past 12 weeks.
  • Use of methotrexate, cyclosporine, or apremilast in the past 4 weeks.
  • History of or allergies to any contents in the orticumab formulation.
  • A history of any abnormalities in cardiac rhythm or conduction.
  • A history of prolonged or a family history of long QT-syndrome at Screening.
  • A history of first, second or third-degree atrioventricular (AV) block, or AV dissociation.
  • A history of complete bundle branch block.
  • Unstable angina pectoris, myocardial infarction, , or stroke within 3 months prior to Screening, or participants who have undergone percutaneous coronary intervention or a coronary artery bypass graft within 6 months prior to Screening or who are due to undergo these procedures at the time of Screening.
  • Severe congestive heart failure ( III or IV).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
77 participants (actual)

Study arms

  • Active comparator
    Active Treatment

    Dosage: Repeating intravenous dose. Administered by infusion over 30 minutes. Frequency and duration: once weekly x 4 weeks, then once monthly x 2 months.

    Drug: Orticumab

  • Placebo comparator
    Placebo

    Dosage: Repeating intravenous dose. Administered by infusion over 30 minutes. Frequency and duration: once weekly x 4 weeks, then once monthly x 2 months.

    Drug: Placebo

Interventions

  • A human recombinant monoclonal antibody against a specific oxidized low-density lipoprotein (oxLDL) epitope

    Also known as: MLDL1278a; BI-204; Anti-oxLDL Antibody

  • DrugPlacebo

    Placebo for orticumab, containing all components of formulation except the active ingredient

06

What researchers measure

Primary outcomes

  1. Mean Percent Change From Baseline in Psoriasis Area Severity Index (PASI)

    PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease)

    Time frame: 106 days (Week 15)

  2. Percentage of Participants Achieving Treatment Success by the 5-point Static Investigator's Global Assessment Modified 2011 Version (sIGA) Score

    Percentage of participants achieving treatment success (clear =0 or almost clear =1) and greater than or equal to (\>=) 2 Point Improvement at Week 15 on the sIGA scale

    Time frame: 106 days (Week 15)

Secondary outcomes

  1. Mean Percent Change From Baseline in Psoriasis Area Severity Index (PASI)

    PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease)

    Time frame: Weeks 1, 3, 7, and 11

  2. Percentage of Participants Achieving PASI75 and PASI50

    PASI75 is a 75 percent reduction in PASI score. PASI50 is a 50 percent reduction in PASI score

    Time frame: Weeks 1, 3, 7, and 11

  3. Mean Percent Change in Baseline in Body Surface Area (BSA) % Involvement

    Minimum: 0 percent, Maximum: 100 percent. Higher percentage indicates more skin with psoriasis.

    Time frame: Weeks 1, 3, 7, 11, 15

  4. Mean Change From Baseline in Dermatology Life Quality Index (DLQI) Score

    DLQI is a ten-question questionnaire used to measure the impact of skin disease on the quality of life of an affected person. Each question is scored from 0 to 3, giving a possible score range from 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life).

    Time frame: Weeks 3, 7, 11, 15

  5. Mean Change From Baseline in Itch Numerical Rating Scale (INRS) Score

    The Itch NRS is a self-administered subject reported outcome questionnaire that is completed during protocol specified clinic visits. Participants indicate itch severity by circling the integer that best describes the worst level of itching due to psoriasis in the past 24 h on an 11-point scale anchored at 0, representing 'no itching' and 10, representing 'worst itch imaginable'.

    Time frame: Weeks 3 and 15

Other outcomes

  1. Change in Coronary Artery Inflammation by CCTA

    Change in coronary artery perivascular fat attenuation index (FAI) measured by coronary computed tomographic angiography (CCTA) as report in FAI-Score. \- Fat Attenuation Index score is a standardized measurement of coronary inflammation for each coronary artery (adjusted for age, sex as well as technical, biological, and anatomical characteristics) to allow individualized interpretation of the degree of coronary inflammation. FAI-Score range from 0-100. Higher FAI-Score means more inflammation. \- CaRi-Heart® Risk Score provides an individualized absolute risk of a fatal cardiac event within the next 8 years, incorporating: 1. Inflammation measured by FAI-Score 2. Plaque burden 3. Other clinical risk factors. CaRi-Heart Risk Score range from 0-100. It's a percentage that categorizes risk into three levels: Low (≤5%), Medium (5-10%), and High (\>10%). Higher CaRi-Heart Risk Score means higher risk. We reported the change in FAI Score and CaRi-Heart Risk Score from baseline here.

    Time frame: 106 days (Week 15)

  2. Change in Coronary Artery Plaque Burden by CCTA

    Change in total, noncalcified and low attenuation coronary artery plaque volume some measurements have inter-quartile of 0 and median of 0 because most of the participants have a baseline value of 0 (no plaque at baseline) and remain no changes during the trial.

    Time frame: 106 days (Week 15)

07

Results

Posted May 11, 2026
Limitations and caveats
The study was randomized at a 2:1 ratio (orticumab: placebo). This resulted in lower overall statistical power to detect a difference \<7% improvement between groups.

Participant flow

The trial was conducted at 21 clinical sites in the United States.

Participant flow — Overall Study
MilestoneActive TreatmentPlacebo
Started5225
Completed4020
Not completed125
Withdrew: Lost to follow-up51
Withdrew: Withdrawal by subject54
Withdrew: Adverse event10
Withdrew: Covid 19 infection10

Outcome measures

PrimaryMean Percent Change From Baseline in Psoriasis Area Severity Index (PASI)

PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease)

Time frame:
106 days (Week 15)
Reported as:
Mean · Percentage change of score
Mean Percent Change From Baseline in Psoriasis Area Severity Index (PASI)
Percentage change of scoreActive TreatmentPlacebo
Mean Percent Change From Baseline in Psoriasis Area Severity Index (PASI)-25.45 ± 26.552-18.95 ± 25.165
PrimaryPercentage of Participants Achieving Treatment Success by the 5-point Static Investigator's Global Assessment Modified 2011 Version (sIGA) Score

Percentage of participants achieving treatment success (clear =0 or almost clear =1) and greater than or equal to (\>=) 2 Point Improvement at Week 15 on the sIGA scale

Time frame:
106 days (Week 15)
Reported as:
Count of participants · Participants
Percentage of Participants Achieving Treatment Success by the 5-point Static Investigator's Global Assessment Modified 2011 Version (sIGA) Score
ParticipantsActive TreatmentPlacebo
Percentage of Participants Achieving Treatment Success by the 5-point Static Investigator's Global Assessment Modified 2011 Version (sIGA) Score1 ± 0.591 ± 0.75
SecondaryMean Percent Change From Baseline in Psoriasis Area Severity Index (PASI)

PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease)

Time frame:
Weeks 1, 3, 7, and 11
Reported as:
Mean · PASI score % change
Mean Percent Change From Baseline in Psoriasis Area Severity Index (PASI)
PASI score % changeActive TreatmentPlacebo
Week 1-3.46 ± 9.757-1.24 ± 7.099
Week 3-12.94 ± 18.529-8.28 ± 9.206
week 7-20.14 ± 21.340-5.47 ± 15.341
Week 11-22.50 ± 23.844-14.34 ± 17.159
SecondaryPercentage of Participants Achieving PASI75 and PASI50

PASI75 is a 75 percent reduction in PASI score. PASI50 is a 50 percent reduction in PASI score

Time frame:
Weeks 1, 3, 7, and 11
Reported as:
Count of participants · Participants
Percentage of Participants Achieving PASI75 and PASI50
ParticipantsActive TreatmentPlacebo
Week 1 - PASI 50 — Achieved00
Week 1 - PASI 50 — Not achieved5124
Week 1 - PASI 75 — Achieved00
Week 1 - PASI 75 — Not achieved5124
Week 3 - PASI 50 — Achieved20
Week 3 - PASI 50 — Not achieved4621
Week 3 - PASI 75 — Achieved20
Week 3 - PASI 75 — Not achieved4621
Week 7 - PASI 50 — Achieved50
Week 7 - PASI 50 — Not achieved4022
Week 7 - PASI 75 — Achieved10
Week 7 - PASI 75 — Not achieved4422
Week 11 - PASI 50 — Achieved50
Week 11 - PASI 50 — Not achieved3921
Week 11 - PASI 75 — Achieved20
Week 11 - PASI 75 — Not achieved4221
SecondaryMean Percent Change in Baseline in Body Surface Area (BSA) % Involvement

Minimum: 0 percent, Maximum: 100 percent. Higher percentage indicates more skin with psoriasis.

Time frame:
Weeks 1, 3, 7, 11, 15
Reported as:
Mean · percentage change of body surface
Mean Percent Change in Baseline in Body Surface Area (BSA) % Involvement
percentage change of body surfaceActive TreatmentPlacebo
Week 1-1.02 ± 6.045-1.93 ± 5.087
Week 3-6.85 ± 18.220-6.88 ± 10.516
Week 7-13.51 ± 22.010-0.66 ± 20.653
Week 11-14.34 ± 22.567-4.99 ± 39.048
Week 15-15.49 ± 27.099-6.55 ± 37.072
SecondaryMean Change From Baseline in Dermatology Life Quality Index (DLQI) Score

DLQI is a ten-question questionnaire used to measure the impact of skin disease on the quality of life of an affected person. Each question is scored from 0 to 3, giving a possible score range from 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life).

Time frame:
Weeks 3, 7, 11, 15
Reported as:
Mean · score
Mean Change From Baseline in Dermatology Life Quality Index (DLQI) Score
scoreActive TreatmentPlacebo
Week 3-3.6 ± 4.01-2.0 ± 4.07
Week 7-3.5 ± 4.39-2.2 ± 4.21
Week 11-3.8 ± 4.20-2.8 ± 4.93
Week 15-4.1 ± 4.5-2.7 ± 5.19
SecondaryMean Change From Baseline in Itch Numerical Rating Scale (INRS) Score

The Itch NRS is a self-administered subject reported outcome questionnaire that is completed during protocol specified clinic visits. Participants indicate itch severity by circling the integer that best describes the worst level of itching due to psoriasis in the past 24 h on an 11-point scale anchored at 0, representing 'no itching' and 10, representing 'worst itch imaginable'.

Time frame:
Weeks 3 and 15
Reported as:
Mean · scores on a scale
Mean Change From Baseline in Itch Numerical Rating Scale (INRS) Score
scores on a scaleActive TreatmentPlacebo
Week 36.2 ± 2.556.7 ± 2.13
Week 156.1 ± 2.717.1 ± 2.59
Other pre-specifiedChange in Coronary Artery Inflammation by CCTA

Change in coronary artery perivascular fat attenuation index (FAI) measured by coronary computed tomographic angiography (CCTA) as report in FAI-Score. \- Fat Attenuation Index score is a standardized measurement of coronary inflammation for each coronary artery (adjusted for age, sex as well as technical, biological, and anatomical characteristics) to allow individualized interpretation of the degree of coronary inflammation. FAI-Score range from 0-100. Higher FAI-Score means more inflammation. \- CaRi-Heart® Risk Score provides an individualized absolute risk of a fatal cardiac event within the next 8 years, incorporating: 1. Inflammation measured by FAI-Score 2. Plaque burden 3. Other clinical risk factors. CaRi-Heart Risk Score range from 0-100. It's a percentage that categorizes risk into three levels: Low (≤5%), Medium (5-10%), and High (\>10%). Higher CaRi-Heart Risk Score means higher risk. We reported the change in FAI Score and CaRi-Heart Risk Score from baseline here.

Time frame:
106 days (Week 15)
Reported as:
Mean · scores on a scale
Change in Coronary Artery Inflammation by CCTA
scores on a scaleActive TreatmentPlacebo
CaRi-Heart Score-2.34 ± 7.9230.83 ± 4.393
FAI Score - Left Anterior Descending Artery4.215 ± 3.03113.119 ± 1.7936
FAI Score - Left Circumflex Coronary Artery-0.808 ± 2.21850.332 ± 1.5630
FAI Score - Right Coronary Artery-2.288 ± 6.50150.022 ± 2.5323
Other pre-specifiedChange in Coronary Artery Plaque Burden by CCTA

Change in total, noncalcified and low attenuation coronary artery plaque volume some measurements have inter-quartile of 0 and median of 0 because most of the participants have a baseline value of 0 (no plaque at baseline) and remain no changes during the trial.

Time frame:
106 days (Week 15)
Reported as:
Median · cubic millimeter
Change in Coronary Artery Plaque Burden by CCTA
cubic millimeterActive TreatmentPlacebo
Low attenuation plaque volume0 (0 to 0)0 (0 to 0.115)
Non-calcified plaque volume0.160 (0 to 1.280)0.320 (0 to 10.255)
Total plaque volume1.160 (0 to 5.310)1.535 (0 to 23.955)

Adverse events

Collected over From enrollment until end of follow-up, up to 15 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active Treatment0/52 (0%)2/52 (3.8%)4/52 (7.7%)
Placebo0/25 (0%)0/25 (0%)5/25 (20%)
Most frequent serious events
Most frequent serious events
EventActive TreatmentPlacebo
ConstipationGastrointestinal disorders1/520/25
Bone abscessInfections and infestations1/520/25
Most frequent other events
Most frequent other events
EventActive TreatmentPlacebo
Covid-19 infectionInfections and infestations1/523/25
HeadacheNervous system disorders3/522/25

Baseline characteristics

Intent-to-treat (ITT) analysis population included all randomized participants.

Age, Continuous
Age, Continuous(years)Active TreatmentPlaceboTotal
Mean52 ± 10.650.5 ± 9.851.5 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Active TreatmentPlaceboTotal
Female201333
Male321244
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Active TreatmentPlaceboTotal
Hispanic or Latino311849
Not Hispanic or Latino21728
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Active TreatmentPlaceboTotal
White482371
Black303
Asian112
American Native011
08

Study locations

13 sites
  • CCT- Research at the center for Dermatology and Plastic Surgery
    Scottsdale, Arizona 85260, United States
  • Derm Institute & Skin Care Ctr., Inc.
    Santa Monica, California 90404, United States
  • Orange County Research Center
    Tustin, California 92780, United States
  • Blue Coast Research Center
    Vista, California 92083, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • Las Vegas Clinical Trials
    Las Vegas, Nevada 89030, United States
  • Excel Clinical Research
    Las Vegas, Nevada 89109, United States
  • Vital Prospects Clinical Research Institute, PC
    Tulsa, Oklahoma 85260, United States
  • SMS Clinical Research
    Mesquite, Texas 75149, United States
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
  • Center for Clinical Studies, LTD.LLP
    Webster, Texas 77598, United States
  • CCT Research - Springville Dermatology
    Springville, Utah 84663, United States
09

References and documents

Publications

  • Farina CJ, Davidson MH, Shah PK, Stark C, Lu W, Shirodaria C, Wright T, Antoniades CA, Nilsson J, Mehta NN. Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial. Cardiovasc Res. 2024 May 29;120(7):678-680. doi: 10.1093/cvr/cvae057. No abstract available. PubMed 38523341 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Nov 2022, 16 months.

Results were first posted in May 2026, 3 years 6 months after primary completion.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 16 months is above that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2021
First posted
Mar 2, 2021
StartActual
Jun 30, 2021
Primary completionActual
Nov 11, 2022
CompletionActual
Nov 11, 2022
Results first posted
May 11, 2026
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04776629
Lead sponsor
Abcentra
Responsible party
Sponsor
First posted
Mar 2, 2021
Start date
Jun 30, 2021
Primary completion
Nov 11, 2022
Completion
Nov 11, 2022
Results posted
May 11, 2026
Last update
May 11, 2026

Study contacts

Joel Neutel, MD
principal investigator · Orange County Research Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MLDL1278A

Start the discussion